Sigrun Schulze-Erkens
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.
Journal: Molecular cancer therapeutics
Published: June 29, 2023
Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.
Journal: Cells
Published: October 09, 2022
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 21, 2020
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Journal: British journal of cancer
Published: March 18, 2020
CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance.
Journal: Scientific reports
Published: June 17, 2019
Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
Journal: The Prostate
Published: February 11, 2018
Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
Journal: The Prostate
Published: August 25, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026